文献速递肝病消化道肿瘤与早癌

基于血液的生物标志物用于肝细胞癌筛查:超声时代即将终结?

Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
PubMed 文献 · J Hepatol · 2022-09-08

综述指出当前肝细胞癌筛查推荐每半年一次腹部超声联合或不联合血清甲胎蛋白,但该策略存在早期敏感性欠佳、假阳性、操作者间差异和依从性差等缺陷。基于血液的生物标志物有望克服这些障碍,但需经过病例对照验证及前瞻性队列验证,且需满足性能与实操要求才可能替代超声。

要点

  • 当前筛查推荐每半年一次腹部超声联合或不联合血清甲胎蛋白,用于肝硬化及慢性乙型肝炎感染人群。
  • 超声筛查存在早期敏感性欠佳、假阳性、操作者间差异和依从性差等缺陷。
  • 血液生物标志物需经病例对照及前瞻性队列验证,并克服实操障碍后才可能替代超声。

核心结论

  • 血液生物标志物前景显著,但需充分验证并克服多个操作障碍后方可临床实施。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • 当前筛查策略为每半年一次腹部超声联合或不联合血清甲胎蛋白,用于肝硬化及慢性乙型肝炎感染人群。
  • 超声筛查存在早期敏感性欠佳、假阳性及后续伤害、操作者间差异和依从性差等缺陷。
  • 肝细胞癌早期检测研究(Hepatocellular Carcinoma Early Detection Study)和德克萨斯肝细胞癌联盟(Texas Hepatocellular Carcinoma Consortium)等验证队列正在成熟。

关键数值与推荐

  • 生物标志物临床筛查应用前需多步骤验证,包括病例对照验证及随后在高危患者前瞻性队列中的验证。
  • 候选生物标志物须显示足够检测性能并克服实际障碍才可能替代腹部超声。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, in part because of inadequate early detection strategies. Current recommendations for screening consist of semi-annual abdominal ultrasound with or without serum alpha-fetoprotein in patients with cirrhosis and in demographic subgroups with chronic hepatitis B infection. However, this screening strategy has several deficiencies, including suboptimal early-stage sensitivity, false positives with subsequent harms, inter-operator variability in ultrasound performance, and poor adherence. A blood-based biomarker with sufficient performance characteristics for early-stage disease could overcome several of these barriers to improving early-stage detection. However, prior to use of a biomarker for screening in clinical practice, a multistep validation is required in order to understand test performance characteristics. These steps include case-control validation, followed by validation in prospective cohorts of at-risk patients. Until recently, we lacked adequate longitudinal validation cohorts for early HCC detection; however, several validation cohorts are maturing, including the Hepatocellular Carcinoma Early Detection Study and the Texas Hepatocellular Carcinoma Consortium, which will allow for rigorous validation of candidate biomarkers. While there are several promising biomarkers awaiting validation, in order to supplant abdominal ultrasound, a candidate biomarker must show adequate test performance and overcome practical hurdles to ensure adoption in clinical practice. The promise of blood-based biomarkers is significant, especially given the limitations of ultrasound-based screening; however, they require adequate validation and several logistical obstacles must be overcome prior to clinical implementation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Parikh ND, Tayob N, Singal AG, et al. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol. 2022. PMID: 36089157. doi:10.1016/j.jhep.2022.08.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。